Tetracosactide
Brand names: Synacthen, Synacthen Depot
Tetracosactide is a synthetic adrenocorticotrophic hormone (ACTH) analogue used mainly as a diagnostic agent to test adrenocortical function (the short Synacthen test). A depot form has also been used therapeutically in certain inflammatory conditions.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a synthetic polypeptide corresponding to the first part of the ACTH molecule that stimulates the adrenal cortex, via melanocortin receptors, to synthesise and release corticosteroids, principally cortisol.
Prescribing in practice
- It is contraindicated in patients with a history of allergic disorders or previous hypersensitivity to ACTH preparations, as it can cause serious anaphylactic reactions, and facilities to treat anaphylaxis should be available.
- A normal cortisol response to the test does not exclude all forms of adrenal insufficiency, and results must be interpreted in clinical context.
- When used therapeutically it produces the same adverse effects as systemic corticosteroids and does not allow the precise control of an oral steroid dose.
Monitoring
For the diagnostic test, monitor plasma cortisol before and after administration and observe the patient for any hypersensitivity reaction.
Counselling the patient
- This is usually given as a one-off injection as part of a hormone test, with a blood sample taken before and after.
- Tell the clinician beforehand if you have any history of allergy or asthma.
- Report any rash, wheeze, swelling, or faintness after the injection.
Evidence & guidelines
Its use in assessing adrenocortical reserve is well established and forms the basis of the standard short synacthen test.
Reference: UK Endocrine Society; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Duke Treadmill Score · Coronary Artery Disease
- Pre-test Probability for Stable CAD (ESC 2019) · Chest Pain
- Adrenal Insufficiency Assessment · Adrenal
- Thyroid Function Test Interpretation · Thyroid Disease
- Dix-Hallpike Test Interpretation / BPPV Assessment · Vestibular
- Snellen Visual Acuity Interpretation · Ophthalmology
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016